CSL Limited (CSLLY)
OTCMKTS
· Delayed Price · Currency is USD
89.30
+0.57 (0.64%)
Nov 21, 2024, 4:00 PM EST
CSL Limited Revenue
In the fiscal year ending June 30, 2024, CSL Limited had annual revenue of $14.80B with 11.19% growth. CSL Limited had revenue of $6.75B in the half year ending June 30, 2024, with 49.24% growth.
Revenue
14.80B
Revenue Growth
+11.19%
P/S Ratio
n/a
Revenue / Employee
452.63K
Employees
32,698
Market Cap
87.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
| Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
| Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
| Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
| Jun 30, 2020 | 9.15B | 612.20M | 7.17% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |
CSL Limited News
- 4 weeks ago - New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza - PRNewsWire
- 5 weeks ago - CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PRNewsWire
- 5 weeks ago - CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines - PRNewsWire
- 6 weeks ago - GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report - Benzinga
- 6 weeks ago - CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza - PRNewsWire
- 6 weeks ago - Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply - BNN Bloomberg
- 7 weeks ago - CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations - PRNewsWire
- 7 weeks ago - Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination - Business Wire